Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.
The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Findings from a large study of bladder-sparing treatments for muscle-invasive bladder cancer support the routine use of 5-fluorouracil and mitomycin C concomitantly with radiation therapy.
N-803 is an IL-15 superagonist complex consisting of an IL-15 mutant bound to an IL-15 receptor α/IgG1 Fc fusion protein
Padcev is the first antibody-drug conjugate approved for advanced urothelial cancer patients.
Nadofaragene firadenovec, an adenovirus vector-based gene therapy containing the gene interferon alfa-2b, achieved a complete response in 53% of patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease at 3 months.
Higher body mass index, a history of chronic obstructive pulmonary diseases, and black race are associated with an increased risk of reoperation within 30 days of racial cystectomy, a study found.
This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.
Laparoscopic, robotic-assisted, and open radical cystectomy are associated with similar long-term oncologic outcomes among patients with muscle-invasive or high-risk nonmuscle-invasive bladder cancer, according to findings from the CORAL study, the only randomized trial comparing the 3 surgical approaches. In the study, investigators randomly assigned patients with muscle-invasive bladder cancer (MIBC, 38 patients) or high-risk non-muscle…
FDA label change linked to decrease in immunotherapy use, increases in chemotherapy use, PD-L1 testing